SCHEMBL3337856

SCHEMBL3337856

Clc1cc2cnc3ccccc3n2c1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.46
ALDH1A1 P00352 2/20 0.46
HPGD P15428 2/20 0.46
HSD17B10 Q99714 2/20 0.46
GLA P06280 1/20 0.46
GAA P10253 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.41
KMT2A Q03164 2/20 0.41
MAPK1 P28482 2/20 0.41
MAPT P10636 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
GMNN O75496 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
ALOX12 P18054 1/20 0.41
NFKB1 P19838 1/20 0.41
APEX1 P27695 1/20 0.41
HIF1A Q16665 1/20 0.41
FGFR1 P11362 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29711837 0.77 ALDH1A1 (0.50) KDM4EALDH1A1HPGDHSD17B10GLA
SCHEMBL4511748 0.77 ALDH1A1 (0.50) KDM4EALDH1A1HPGDHSD17B10GLA
SCHEMBL31612313 0.75 KDM4E (0.49) KDM4EALDH1A1HPGDHSD17B10GLA
SCHEMBL3344499 0.74 SMN1; SMN2 (0.41) KDM4EALDH1A1HPGDHSD17B10GLA
SCHEMBL29284760 0.72 HSD17B10 (0.46) KDM4EALDH1A1HPGDHSD17B10GLA
SCHEMBL31531870 0.68 KDM4E (0.49) KDM4EALDH1A1HPGDHSD17B10GLA
SCHEMBL17221898 0.68 KDM4E (0.49) KDM4EALDH1A1HPGDHSD17B10GLA
SCHEMBL29893137 0.66 TDP1 (0.41) KDM4EALDH1A1HPGDHSD17B10GLA
SCHEMBL31612341 0.66 HSD17B10 (0.42) KDM4EALDH1A1HPGDHSD17B10GLA
SCHEMBL9216927 0.66 ALDH1A1 (0.50) KDM4EALDH1A1HPGDHSD17B10GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100152180-A1 4-oxo-4,5-dihydropyrrolo[1,2-A)quinoxaline derivatives as inhibitors of poly(ADP-ribose) polymerase (PARP) ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2010-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152180-A1 4-oxo-4,5-dihydropyrrolo[1,2-A)quinoxaline derivatives as inhibitors of poly(ADP-ribose) polymerase (PARP) PARP1, PARP2, PARP4 KDM4E 1668/4885ALDH1A1 185/4885HPGD 764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.